VTEU COVID-19 Trials

Remdesivir now described by Anthony Fauci, MD, the director of the National Institute of Allergy and Infectious Diseases (NIAID), as the new standard of care in treating patients hospitalized with COVID-19.

Investigators currently anticipate enrolling more than 1,000 participants. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial.

The Kaiser Washington Vaccine and Treatment Evaluation Unit, named by the NIH National Institute of Allergy and Infectious Diseases and the Infectious Diseases Clinical Research Consortium as the clinical trial site for a first-in-humans, phase I of a new vaccine study to prevent coronavirus disease 2019 (COVID-19)

Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in a Phase 1 clinical trial of an investigational vaccine designed to prevent coronavirus disease 2019 (COVID-19).

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

Logos and headshots of the leadership group
VTEUs
Logos and headshots for each VTEU

NIAID Division of Microbiology and Infectious Diseases (DMID)